Telomir Pharmaceuticals is a preclinical stage company focused on the science of lengthening telomere caps, which the company believes will extend human lifespans and improve quality of life as people age. Preclinical tests showed that the company's signature therapy, Telomir-1, appeared to address insulin resistance and achieving reversal to near pre-diabetic levels. These results add to previous testing results showing a myriad of potential life improving and extending benefits.
